Loading clinical trials...
Loading clinical trials...
Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) to Treat Patients With NYHA Stage III or IV Heart Failure (HF) With Persistent Congestion and Worsening Renal Function as a Result of Cardiorenal Syndrome (CRS) That is Resistant to Optimal Medical Therapy Including Loop Diuretics
Conditions
Interventions
Selective Cytopheretic Device
Locations
1
United States
University of Michigan
Ann Arbor, Michigan, United States
Start Date
September 1, 2025
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2027
Last Updated
September 27, 2024
NCT07037459
NCT07550790
NCT06874556
NCT07318103
NCT07113223
NCT05373940
Lead Sponsor
Lenar Yessayan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions